---
reference_id: "PMID:37088804"
title: "Lynch syndrome: influence of additional susceptibility variants on cancer risk."
authors:
- Vibert R
- Hasnaoui J
- Perrier A
- Lefebvre A
- Colas C
- Dhooge M
- Basset N
- Chansavang A
- Desseignes C
- Duval A
- Farelly S
- Hamzaoui N
- Laurent-Puig P
- Metras J
- Moliere D
- Muleris M
- Netter J
- Touat M
- Bielle F
- Labreche K
- Nicolle R
- Perkins G
- Warcoin M
- Coulet F
- Benusiglio PR
journal: Eur J Hum Genet
year: '2023'
doi: 10.1038/s41431-023-01367-z
content_type: abstract_only
---

# Lynch syndrome: influence of additional susceptibility variants on cancer risk.
**Authors:** Vibert R, Hasnaoui J, Perrier A, Lefebvre A, Colas C, Dhooge M, Basset N, Chansavang A, Desseignes C, Duval A, Farelly S, Hamzaoui N, Laurent-Puig P, Metras J, Moliere D, Muleris M, Netter J, Touat M, Bielle F, Labreche K, Nicolle R, Perkins G, Warcoin M, Coulet F, Benusiglio PR
**Journal:** Eur J Hum Genet (2023)
**DOI:** [10.1038/s41431-023-01367-z](https://doi.org/10.1038/s41431-023-01367-z)

## Content

1. Eur J Hum Genet. 2023 Sep;31(9):1078-1082. doi: 10.1038/s41431-023-01367-z.
Epub  2023 Apr 24.

Lynch syndrome: influence of additional susceptibility variants on cancer risk.

Vibert R(1), Hasnaoui J(2), Perrier A(2), Lefebvre A(3)(4), Colas C(5)(6), 
Dhooge M(7), Basset N(2), Chansavang A(8)(9), Desseignes C(2), Duval A(4), 
Farelly S(7), Hamzaoui N(8)(9), Laurent-Puig P(10), Metras J(11), Moliere D(10), 
Muleris M(2)(4), Netter J(10), Touat M(12)(13), Bielle F(14), Labreche K(15), 
Nicolle R(2), Perkins G(10), Warcoin M(5), Coulet F(2)(4), Benusiglio 
PR(2)(4)(11).

Author information:
(1)Département de Génétique médicale et Institut Universitaire de Cancérologie, 
Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, 47-83 Boulevard de 
l'Hôpital, F-75013, Paris, France. roseline.vibert@aphp.fr.
(2)Département de Génétique médicale et Institut Universitaire de Cancérologie, 
Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, 47-83 Boulevard de 
l'Hôpital, F-75013, Paris, France.
(3)Laboratoire de Probabilités, Statistique et Modélisation, CNRS UMR 8001, 
Sorbonne Université, Paris, France.
(4)Sorbonne Université, INSERM, Unité Mixte de Recherche Scientifique 938 et 
SIRIC CURAMUS, Centre de Recherche Saint-Antoine, Equipe Instabilité des 
Microsatellites et Cancer, 184 rue du Faubourg Saint-Antoine, F-75012, Paris, 
France.
(5)Département de Génétique, Institut Curie, Paris, France.
(6)INSERM U830, Université Paris Cité, Paris, France.
(7)Service de Gastroentérologie et Oncologie digestive, Hôpital Cochin, AP-HP 
Centre, Paris, France.
(8)Fédération de Génétique et Médecine Génomique, Hôpital Cochin, AP-HP, 
Centre-Université Paris Cité, Paris, France.
(9)Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris Cité, CARPEM, 
Paris, France.
(10)Institut du Cancer Paris CARPEM, APHP, Département de Médecine Génomique des 
tumeurs et cancers, APHP, Centre - Université Paris Cité, Paris, France.
(11)Service de Chirurgie Générale et Digestive, Hôpital Saint-Antoine AP-HP, 
Sorbonne Université, 184, rue du Faubourg Saint-Antoine, 75012, Paris, France.
(12)Service de Neurologie 2 Mazarin, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne 
Université, 47-83 Boulevard de l'Hôpital, F-75013, Paris, France.
(13)Sorbonne Université, Institut du Cerveau-Paris Brain Institute - ICM, 
Inserm, CNRS, SIRIC CURAMUS, Onconeurothèque, AP-HP 47-83 Boulevard de 
l'Hôpital, F-75013, Paris, France.
(14)Département de Neuropathologie Raymond Escourolle, Hôpital 
Pitié-Salpêtrière, AP-HP, Sorbonne Université, 47-83 Boulevard de l'Hôpital, 
F-75013, Paris, France.
(15)Sorbonne-Université, équipe BMX-UMS PASS-91 Bd de l'hôpital, F-75013, Paris, 
France.

Some patients with Lynch syndrome (LS) have extreme phenotypes, i.e. cancer 
before the recommended screening age, or cancer for which there are no screening 
guidelines. We made the hypothesis that additional germline variants in cancer 
susceptibility genes (CSG) could explain some of these phenotypes. We compared 
the prevalence of additional CSG variants in LS patients with a cancer diagnosis 
before age 30 (early-onset, EO group) and after 40 (usual-onset, UO group). 
While there was no overall difference, we did find an excess of pathogenic 
variants and variants of unknown significance in EO cases when only 
gastrointestinal CSG were considered (OR 2.25; 95% CI: 1.01-5.06, p 
value = 0.04). Four EO cases stood out: two with POLE/POLD1 variants in the key 
exonuclease domain, one with a BMPR1A duplication and one with an EPCAM 
deletion. Additional germline variants should be considered in future screening 
recommendations, as they might influence cancer risk.

© 2023. The Author(s), under exclusive licence to European Society of Human 
Genetics.

DOI: 10.1038/s41431-023-01367-z
PMCID: PMC10474080
PMID: 37088804 [Indexed for MEDLINE]

Conflict of interest statement: PRB has received honoraria from AstraZeneca, MSD 
and BMS. The other authors declare no competing interests.